Free Cash Flow (Quarterly) Chart

View Free Cash Flow (Quarterly) for MIST.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Free Cash Flow (Quarterly) Chart
Start Trial

Historical Free Cash Flow (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
June 30, 2026 -22.56M
March 31, 2026 -16.10M
December 31, 2025 -12.60M
September 30, 2025 -9.840M
June 30, 2025 -13.04M
March 31, 2025 -13.96M
December 31, 2024 -6.334M
September 30, 2024 -7.042M
June 30, 2024 -5.954M
March 31, 2024 -8.934M
December 31, 2023 -9.252M
September 30, 2023 -12.25M
June 30, 2023 -10.68M
March 31, 2023 -13.94M
December 31, 2022 -11.51M
Date Value
September 30, 2022 -11.08M
June 30, 2022 -14.03M
March 31, 2022 -13.95M
December 31, 2021 -12.29M
September 30, 2021 -9.121M
June 30, 2021 0.8371M
March 31, 2021 -12.47M
December 31, 2020 -9.679M
September 30, 2020 -8.406M
June 30, 2020 -16.06M
March 31, 2020 -18.08M
December 31, 2019 -16.71M
September 30, 2019 -8.939M
June 30, 2019 -11.45M
March 31, 2019 -14.73M

Free Cash Flow Definition

Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.

Read full definition.

Free Cash Flow (Quarterly) Range, Past 5 Years

View Free Cash Flow (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Free Cash Flow (Quarterly) Benchmarks

View Free Cash Flow (Quarterly) Benchmarks
Start Trial
InMed Pharmaceuticals, Inc. -1.759M
NervGen Pharma Corp. -4.086M
Clearmind Medicine, Inc. -1.792M
Lexaria Bioscience Corp. -1.661M
Target Group, Inc. (Canada) -0.2294M